Cited in boardrooms, legal proceedings & government briefings since 2017
Medical cannabis sales and registered patients in Estonia, 2025 actuals and the 2027 forecast. Forecasts to 2030 are in the Estonia data pack.
Medical sales, EUR
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| Medical sales | €382.3k | €423.1k | €464k | |||
| Patients | 261 | 289 | 317 |
Forecasts to 2030 — sales, patients and the full Estonia series — are in the Estonia data pack, or scoped to your question in a bespoke brief.
See the data pack Request a briefSource: Prohibition Partners — Global Medical Cannabis Market Review (2026, updated April 2026) & The European Cannabis Report (2025)
From International Cannabis Weekly, our free global briefing.
El Planteo · №263 · 2 Sept 2022 · Hemp & CBD
news.err.ee · №262 · 26 Aug 2022 · Regulation
№237 · 4 Mar 2022 · Hemp & CBD
№122 · 15 Nov 2019 · Regulation
№117 · 11 Oct 2019 · Regulation
№35 · 9 Mar 2018 · Regulation
Medical cannabis is an unlicensed medicine and is only accessible through a special permit in Estonia.
To prescribe medical cannabis in Estonia, a specialist doctor must provide a medical justification for its use for the patient and prove that other licensed treatment methods have been exhausted. The application must be sent to the Estonian State Agency of Medicines (SAM), which a patient submits at a suitable pharmacy which has a licence to handle narcotic substances.
The pharmacy applies to SAM, which decides on granting a permit for the use of an unlicensed medical cannabis product. If positive, the decision is forwarded to the pharmacy which submits an order to the wholesaler which needs to obtain an import permit.
Once the pharmacy acquires it from the wholesaler, the patient can obtain it from the pharmacy. This process can be onerous for patients as many pharmacies and pharmaceutical wholesalers in Estonia may not have experience with cannabis, which may cause problems throughout the chain.
